title: Development of cell-type specific anti-HIV gp120 aptamers for siRNA delivery.
abstract: The global epidemic of infection by HIV has created an urgent need for new classes of antiretroviral agents. The potent ability of small interfering (si)RNAs to inhibit the expression of complementary RNA transcripts is being exploited as a new class of therapeutics for a variety of diseases including HIV. Many previous reports have shown that novel RNAi-based anti-HIV/AIDS therapeutic strategies have considerable promise; however, a key obstacle to the successful therapeutic application and clinical translation of siRNAs is efficient delivery. Particularly, considering the safety and efficacy of RNAi-based therapeutics, it is highly desirable to develop a targeted intracellular siRNA delivery approach to specific cell populations or tissues. The HIV-1 gp120 protein, a glycoprotein envelope on the surface of HIV-1, plays an important role in viral entry into CD4 cells. The interaction of gp120 and CD4 that triggers HIV-1 entry and initiates cell fusion has been validated as a clinically relevant anti-viral strategy for drug discovery. Herein, we firstly discuss the selection and identification of 2'-F modified anti-HIV gp120 RNA aptamers. Using a conventional nitrocellulose filter SELEX method, several new aptamers with nanomolar affinity were isolated from a 50 random nt RNA library. In order to successfully obtain bound species with higher affinity, the selection stringency is carefully controlled by adjusting the conditions. The selected aptamers can specifically bind and be rapidly internalized into cells expressing the HIV-1 envelope protein. Additionally, the aptamers alone can neutralize HIV-1 infectivity. Based upon the best aptamer A-1, we also create a novel dual inhibitory function anti-gp120 aptamer-siRNA chimera in which both the aptamer and the siRNA portions have potent anti-HIV activities. Further, we utilize the gp120 aptamer-siRNA chimeras for cell-type specific delivery of the siRNA into HIV-1 infected cells. This dual function chimera shows considerable potential for combining various nucleic acid therapeutic agents (aptamer and siRNA) in suppressing HIV-1 infection, making the aptamer-siRNA chimeras attractive therapeutic candidates for patients failing highly active antiretroviral therapy (HAART).
authors: Department of Molecular and Cellular Biology, Beckman Research Institute of City of Hope.
authors: Jiehua
authors: J
authors: Zhou
authors: Haitang
authors: H
authors: Li
authors: Jane
authors: J
authors: Zhang
authors: Swiderski
authors: S
authors: Piotr
authors: John
authors: J
authors: Rossi
mesh_terms: D000818:Animals; D052157:Aptamers, Nucleotide / Q000235:genetics*; D016466:CHO Cells; D003101:Collodion; D006224:Cricetinae; D003412:Cricetulus; D005434:Flow Cytometry; D015699:HIV Envelope Protein gp120 / Q000235:genetics*; D018613:Microscopy, Confocal; D034741:RNA, Small Interfering / Q000008:administration & dosage* / Q000235:genetics; D052156:SELEX Aptamer Technique / Q000379:methods*
chemical_list: D052157:Aptamers, Nucleotide; D015699:HIV Envelope Protein gp120; D034741:RNA, Small Interfering; D003101:Collodion